SG11201506813QA - Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists - Google Patents
Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonistsInfo
- Publication number
- SG11201506813QA SG11201506813QA SG11201506813QA SG11201506813QA SG11201506813QA SG 11201506813Q A SG11201506813Q A SG 11201506813QA SG 11201506813Q A SG11201506813Q A SG 11201506813QA SG 11201506813Q A SG11201506813Q A SG 11201506813QA SG 11201506813Q A SG11201506813Q A SG 11201506813QA
- Authority
- SG
- Singapore
- Prior art keywords
- beta
- alpha
- derivatives useful
- integrin antagonists
- naphthyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1305668.4A GB201305668D0 (en) | 2013-03-28 | 2013-03-28 | Avs6 Integrin Antagonists |
| PCT/EP2014/056013 WO2014154725A1 (en) | 2013-03-28 | 2014-03-26 | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201506813QA true SG11201506813QA (en) | 2015-10-29 |
Family
ID=48444909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506813QA SG11201506813QA (en) | 2013-03-28 | 2014-03-26 | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US10023568B2 (zh) |
| EP (2) | EP3360876A1 (zh) |
| JP (1) | JP6095847B2 (zh) |
| KR (2) | KR102042141B1 (zh) |
| CN (1) | CN105189499B (zh) |
| AR (1) | AR095768A1 (zh) |
| AU (1) | AU2014243068C1 (zh) |
| BR (1) | BR112015024530A8 (zh) |
| CA (1) | CA2903358A1 (zh) |
| CL (1) | CL2015002860A1 (zh) |
| CR (1) | CR20150509A (zh) |
| CY (1) | CY1120188T1 (zh) |
| DK (1) | DK2989100T3 (zh) |
| DO (1) | DOP2015000251A (zh) |
| EA (1) | EA027305B1 (zh) |
| ES (1) | ES2665597T3 (zh) |
| GB (1) | GB201305668D0 (zh) |
| HK (1) | HK1214262A1 (zh) |
| HR (1) | HRP20180528T1 (zh) |
| HU (1) | HUE036750T2 (zh) |
| IL (1) | IL241184A0 (zh) |
| LT (1) | LT2989100T (zh) |
| MA (1) | MA38540B1 (zh) |
| ME (1) | ME02987B (zh) |
| MX (1) | MX363288B (zh) |
| NO (1) | NO2989100T3 (zh) |
| NZ (1) | NZ629025A (zh) |
| PE (1) | PE20151606A1 (zh) |
| PH (1) | PH12015502232A1 (zh) |
| PL (1) | PL2989100T3 (zh) |
| PT (1) | PT2989100T (zh) |
| RS (1) | RS57220B1 (zh) |
| SG (1) | SG11201506813QA (zh) |
| SI (1) | SI2989100T1 (zh) |
| TW (1) | TWI632143B (zh) |
| UA (1) | UA114952C2 (zh) |
| UY (1) | UY35505A (zh) |
| WO (1) | WO2014154725A1 (zh) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6215335B2 (ja) | 2013-09-24 | 2017-10-18 | 富士フイルム株式会社 | 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体 |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016142426A1 (en) | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | Tslp binding proteins |
| GB201615588D0 (en) | 2016-09-14 | 2016-10-26 | Glaxosmithkline Ip Dev Ltd | TSLP Binding Proteins |
| GB201604589D0 (en) * | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| MA46746A (fr) | 2016-11-08 | 2019-09-18 | Bristol Myers Squibb Co | Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v |
| PT3538525T (pt) | 2016-11-08 | 2022-08-16 | Bristol Myers Squibb Co | Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina |
| BR112019009129A2 (pt) | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina |
| AU2017359027A1 (en) | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Indazole derivatives as αV integrin antagonists |
| LT3538528T (lt) * | 2016-11-08 | 2021-03-10 | Bristol-Myers Squibb Company | Pirolo amidai, kaip alfa v integrino inhibitoriai |
| EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
| EP4159727A1 (en) | 2017-02-28 | 2023-04-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| WO2019094319A1 (en) | 2017-11-07 | 2019-05-16 | Bristol-Myers Squibb Company | Pyrrolopyrazine derivatives as alpha v integrin inhibitors |
| ES2972512T3 (es) | 2018-03-07 | 2024-06-13 | Pliant Therapeutics Inc | Compuestos de aminoácido y métodos de uso |
| SG11202013027RA (en) * | 2018-06-27 | 2021-01-28 | Pliant Therapeutics Inc | Amino acid compounds with unbranched linkers and methods of use |
| EP3843727A4 (en) * | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS |
| PE20211640A1 (es) | 2018-08-29 | 2021-08-24 | Morphic Therapeutic Inc | INHIBICION DE LA INTEGRINA xvß6 |
| WO2020047207A1 (en) * | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2022183360A1 (en) * | 2021-03-02 | 2022-09-09 | Tsao Yeou Ping | Short synthetic peptide and their uses for treating dry eye disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| BR9813769A (pt) | 1997-12-17 | 2000-10-10 | Merck & Co Inc | Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste. |
| CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| CA2373937A1 (en) | 1999-06-02 | 2000-12-07 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| JP2003502373A (ja) * | 1999-06-23 | 2003-01-21 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
| JP2003510360A (ja) | 1999-10-04 | 2003-03-18 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| IL149313A0 (en) * | 1999-11-08 | 2002-11-10 | Merck & Co Inc | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| WO2001096334A2 (en) | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| ES2280383T3 (es) | 2000-07-26 | 2007-09-16 | MERCK & CO., INC. | Antagonistas de receptores de integrina alfa v. |
| WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| CA2432504A1 (en) | 2001-01-03 | 2002-07-11 | Merck & Co., Inc. | Methods and compositions for treating periodontal disease |
| DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| EA011853B1 (ru) | 2002-03-13 | 2009-06-30 | Байоджен Айдек Ма Инк. | АНТИТЕЛА ПРОТИВ αβ |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| JP2006518333A (ja) | 2002-12-20 | 2006-08-10 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
| US6932865B2 (en) | 2003-04-11 | 2005-08-23 | Lockheed Martin Corporation | System and method of making single-crystal structures through free-form fabrication techniques |
| PL1699512T3 (pl) | 2003-11-03 | 2012-11-30 | Glaxo Group Ltd | Urządzenie do dozowania płynów |
| ES2446417T3 (es) | 2007-03-23 | 2014-03-07 | Amgen Inc. | Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K) |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| WO2009055418A1 (en) | 2007-10-22 | 2009-04-30 | Smithkline Beecham Corporation | Pyridosulfonamide derivatives as pi3 kinase inhibitors |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| EP3052515A4 (en) | 2013-09-30 | 2017-03-15 | The Regents of the University of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| EP3268369A4 (en) | 2015-03-10 | 2018-08-08 | The Regents of The University of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2013
- 2013-03-28 GB GBGB1305668.4A patent/GB201305668D0/en not_active Ceased
-
2014
- 2014-03-26 UA UAA201508518A patent/UA114952C2/uk unknown
- 2014-03-26 ES ES14712666.8T patent/ES2665597T3/es active Active
- 2014-03-26 LT LTEP14712666.8T patent/LT2989100T/lt unknown
- 2014-03-26 BR BR112015024530A patent/BR112015024530A8/pt not_active IP Right Cessation
- 2014-03-26 NO NO14712666A patent/NO2989100T3/no unknown
- 2014-03-26 SI SI201430687T patent/SI2989100T1/en unknown
- 2014-03-26 JP JP2016504647A patent/JP6095847B2/ja not_active Expired - Fee Related
- 2014-03-26 HU HUE14712666A patent/HUE036750T2/hu unknown
- 2014-03-26 US US14/778,095 patent/US10023568B2/en not_active Expired - Fee Related
- 2014-03-26 UY UY0001035505A patent/UY35505A/es not_active Application Discontinuation
- 2014-03-26 PT PT147126668T patent/PT2989100T/pt unknown
- 2014-03-26 MA MA38540A patent/MA38540B1/fr unknown
- 2014-03-26 PL PL14712666T patent/PL2989100T3/pl unknown
- 2014-03-26 PE PE2015002064A patent/PE20151606A1/es active IP Right Grant
- 2014-03-26 AR ARP140101378A patent/AR095768A1/es unknown
- 2014-03-26 AU AU2014243068A patent/AU2014243068C1/en not_active Ceased
- 2014-03-26 EA EA201591503A patent/EA027305B1/ru not_active IP Right Cessation
- 2014-03-26 TW TW103111317A patent/TWI632143B/zh not_active IP Right Cessation
- 2014-03-26 EP EP18157255.3A patent/EP3360876A1/en not_active Withdrawn
- 2014-03-26 SG SG11201506813QA patent/SG11201506813QA/en unknown
- 2014-03-26 MX MX2015013742A patent/MX363288B/es unknown
- 2014-03-26 KR KR1020177024389A patent/KR102042141B1/ko active IP Right Grant
- 2014-03-26 DK DK14712666.8T patent/DK2989100T3/en active
- 2014-03-26 CN CN201480018839.6A patent/CN105189499B/zh not_active Expired - Fee Related
- 2014-03-26 KR KR1020157031064A patent/KR101775085B1/ko active IP Right Grant
- 2014-03-26 NZ NZ629025A patent/NZ629025A/en not_active IP Right Cessation
- 2014-03-26 ME MEP-2018-83A patent/ME02987B/me unknown
- 2014-03-26 RS RS20180537A patent/RS57220B1/sr unknown
- 2014-03-26 WO PCT/EP2014/056013 patent/WO2014154725A1/en active Application Filing
- 2014-03-26 CA CA2903358A patent/CA2903358A1/en not_active Abandoned
- 2014-03-26 EP EP14712666.8A patent/EP2989100B1/en active Active
-
2015
- 2015-09-06 IL IL241184A patent/IL241184A0/en active IP Right Grant
- 2015-09-24 PH PH12015502232A patent/PH12015502232A1/en unknown
- 2015-09-25 CL CL2015002860A patent/CL2015002860A1/es unknown
- 2015-09-28 DO DO2015000251A patent/DOP2015000251A/es unknown
- 2015-09-28 CR CR20150509A patent/CR20150509A/es unknown
-
2016
- 2016-03-02 HK HK16102407.5A patent/HK1214262A1/zh not_active IP Right Cessation
-
2018
- 2018-03-29 HR HRP20180528TT patent/HRP20180528T1/hr unknown
- 2018-05-09 CY CY20181100479T patent/CY1120188T1/el unknown
- 2018-06-13 US US16/007,584 patent/US10450312B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL241184A0 (en) | Naphthyridine derivatives and their use as antagonists of alpha-v-beta-6-integrins | |
| HK1215795A1 (zh) | 鵝膏毒素衍生物 | |
| SG11201506100XA (en) | Pyridazinone-amides derivatives | |
| IL245471A0 (en) | Av-fluorinated integrin antagonists | |
| HK1223090A1 (zh) | -氮雜吲哚衍生物 | |
| ZA201601333B (en) | Oxoquinazolinyl-butanamide derivatives | |
| HRP20180754T1 (hr) | Derivati piperidin uree | |
| HUE038261T2 (hu) | Új azabenzimidazol-származékok | |
| SG11201605189YA (en) | Imidazopyrazinone derivatives | |
| GB201306657D0 (en) | Trestle |